Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Allows Claims on Regulus miRNA Patent Application

Premium

Regulus Therapeutics said this week that the US Patent and Trademark Office has allowed claims in a patent application, owned by Stanford University and exclusively licensed to Regulus, covering methods of antagonizing miR-181a to regulate immune response.

The microRNA has been "shown to regulate the response of immune cells, such as T lymphocytes, to specific stimuli, and modulation of miR-181a could lead to a novel treatment of inflammatory disease," the company said.

Specifically, "the newly allowed claims cover methods of modulating miR-181a in T cells, to raise the T cell receptor signaling threshold, and decrease the sensitivity of T cells to antigen stimulation," Regulus said. "The claims cover the use of a broad class of [miRNA antagonists against] miR-181a," including ones with varying lengths and chemical modifications.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.